Actos

Actos Bladder Cancer Lawsuit

Victims continue to file Actos lawsuits against Takeda Pharmaceuticals

Actos (pioglitazone) is a medication used to regulate insulin in patients diagnosed with type II diabetes.

Actos Bladder Cancer Lawsuit

European Commission advocates Actos as valid treatment

Despite the concerns associated with the linkage between Actos and bladder cancer, the European Commission advocates that Actos is still a

Actos Bladder Cancer Lawsuit

Actos litigation centralized in Louisiana

Actos (pioglitazone) was first introduced in July of 1999 and was designed to aid the body’s sensitivity to insulin in patients that have been diagnosed with type II diabetes.

Actos Bladder Cancer Lawsuit

Actos class action lawsuit filed in Canada

A class action lawsuit has been filed on behalf of consumers who have developed bladder cancer after taking the popular diabetes medication, Actos, manufactured by Japan’s largest drug maker Takeda

Actos Bladder Cancer Lawsuit

Wave of lawsuits continue against Takeda Pharmaceuticals

Hundreds of thousands of patients who claim there is a linkage between Actos® and bladder cancer are currently filing lawsuits

Actos Bladder Cancer Lawsuit

Actos recall not recommended by European health regulators

Actos® was first introduced in July of 1999. Prescribed to treat type II diabetes, the drug became popular for its ability to effectively regulate insulin.

Actos Bladder Cancer Lawsuit

More Actos® Lawsuits filed against Takeda Pharmaceuticals

In September 2010 at the Madison County, Illinois Circuit County Court, Robert and Jewell Bettorf filed an actos bladder cancer lawsuit ag

Actos Bladder Cancer Lawsuit

Centralized Actos® litigation

The U.S.

Actos Bladder Cancer Lawsuit

Actos link to bladder cancer causes sales to drop

The link between Actos medication and bladder cancer has caused sales for Takeda Pharmaceuticals to drop in recent months.

Actos MDL - Consumer Drug Report

U.S. Judicial Panel to decide on Actos MDL

Actos® was released in July of 1999 and was intended for the purpose of increasing the body’s sensitivity to insulin in patients diagnosed with type II diabetes.

Pages